To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me. This week I did a complete re-read of Joel Greenblatt’s classic “The Little Book That Beats The Market.” For any of you that are not familiar with the book, Joel Greenblatt presents his magic formula for picking stocks that his research indicated will beat the market most of the time.
Themes for the next decade: Cannabis, 5G, and EVs
A lot changes in 10 years, and many changes are expected by the time 2030 rolls around. Some key themes have already emerged, and we expect them to continue to impact investing decisions. At the recent Morningstar conference, several panelists joined a discussion about several major themes for the next decade, including cannabis, 5G and Read More
In Chapter 10 Joel Greenblatt presented the results of magic formula stocks. Although he did admit that the formula underperformed the market in one out of every four years tested, and the magic formula underperformed the market in one out of every six year periods tested, he provided what he called the good news as follows:
“Following the formula for any 3 year period in a row, the magic formula beat the market averages 95% of the time (160/169 three-year periods tested! But that is not all! Over three-year periods, if you follow the magic formula, you would have never lost money.”
Considering all that has happened in 2020, I thought it might be interesting to present a screen of stocks based on Joel Greenblatt’s magic formula. Furthermore, I thought it would be refreshing to look for under-followed small and mid-cap companies that could be looked at as potential research candidates capable of generating above-average and attractive total returns.
5 MidCap 2020 Magic Formula Stocks
The magic formula ranks companies based on two factors: return on capital and earnings yield. However, instead of the normal earnings yield calculation which is the inverse of the P/E ratio, Joel Greenblatt utilized a different method for calculating earnings yield. With his method, he utilized pretax operating earnings (EBIT) to enterprise value.
Joel Greenblatt preferred utilizing enterprise value over market value because it takes into account both the price paid to take an equity stake in the business as well as the debt financing used by the company to generate operating earnings. In a preferred EBIT (earnings before interest and taxes) because it considered full purchase price of the business (both equity and debt).
Utilizing the magic formula, I ran a screen for MidCap companies that produced a list of 30. Then, I went through each of those 30 companies and picked 5 that I felt offered the best potential and shown the strongest fundamentals. You will see later, that because these are small companies, they do not all have great operating histories. However, I did feel that these 5 had the best fundamentals out of the 30 companies, and in addition to being magic formula selections, I also like the valuations and future potentials. Therefore, I offer the following 5 magic formula stocks to those investors that are interested in beating the market based on an above-average total future return.
5 MidCap Magic Formula Stocks: Basic Fundamentals and Valuations
The following table provides a summary of the 5 research candidates magic formula selections. As you can see, each of these 5 offer earnings yields and cash flow yields that are significantly above average. Furthermore, even though these are total return selections, 3 of the 5 do pay a dividend.
For each of these 5 selections I offer the following price correlated to EBIT (earnings before interest and taxes) FAST Graphs and return on invested capital FUN Graph on each of the 5 selections. Clearly, each of these research candidates are attractively valued based on historical price to EBIT valuations (the price is either on or below the orange line on each graph) and therefore offer above-average earnings yields on that basis. And they all generate strong returns on invested capital, with a few of them offering spectacular returns on invested capital.
Allison Transmission Holdings (ALSN)
Company Profile courtesy Seeking Alpha
“Allison Transmission Holdings, Inc., together with its subsidiaries, designs, manufactures, and sells commercial and defense fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium- and heavy-tactical U.S. defense vehicles worldwide.
It offers 12 transmission product lines for various applications, including distribution, refuse, construction, fire, and emergency on-highway trucks; school and transit buses; motor homes; energy, mining, and construction off-highway vehicles and equipment; and wheeled and tracked defense vehicles.
The company markets its transmissions under Allison Transmission brand name; and remanufactured transmissions under ReTran brand name. It also sells branded replacement parts, support equipment, aluminum die cast components, and other products necessary to service the installed base of vehicles utilizing its transmissions, as well as defense kits, engineering services, and extended transmission coverage services to various original equipment manufacturers, distributors, and the U.S. government.
The company serves customers through an independent network of approximately 1,500 independent distributor and dealer locations. The company was formerly known as Clutch Holdings, Inc. Allison Transmission Holdings, Inc. was founded in 1915 and is headquartered in Indianapolis, Indiana.”
Catalyst Pharmaceuticals Inc. (CPRX)
Company Profile courtesy Seeking Alpha
“Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.”
EBIX Inc. (EBIX)
Company Profile courtesy Seeking Alpha
“Ebix, Inc. provides on-demand software and e-commerce services and solutions to insurance, financial, healthcare, and e-learning industries in the United States and internationally. It develops and deploys insurance and reinsurance exchanges; provides Software-as-a-Service (SaaS) enterprise solutions in the area of customer relationship management, and front-end and back-end systems; and offers outsourced administrative and risk compliance solutions.
The company operates P&C exchanges primarily in Australia, New Zealand, the United Kingdom, and the United States, which facilitates the exchange of insurance data between brokers and insurance carriers with a focus on the areas of personal and commercial lines. Its exchange related products and services include travel exchanges and money transfer services; foreign exchange and outward remittance services; consumer bill payment services; gift cards for consumers that can be redeemed at various merchants; and technology services for various providers in the areas of lending, wealth and asset management, travel, and logistics.
The company’s insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setting up, customization, training, or consulting. Its risk compliance solutions cover and certificates of insurance creation and tracking; consulting services comprising project management and development; and business process outsourcing services, including domain intensive project management, time, and material based consulting engagements. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.”
HP Inc. (HPQ)
Company Profile courtesy Seeking Alpha
“HP Inc., together with its subsidiaries, provides personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services in the United States and internationally. The company operates through three segments: Personal Systems, Printing, and Corporate Investments.
The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services.
The Printing segment provides consumer and commercial printer hardware, supplies, solutions, and services, as well as scanning devices.
The Corporate Investments segment includes HP Labs and business incubation projects. It serves individual consumers, small- and medium-sized businesses, and large enterprises, including customers in the government, health, and education sectors.
The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.”
Supernus Pharmaceuticals Inc. (SUPN)
Company profile courtesy Seeking Alpha
“Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.
It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
The company’s product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy.
The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.”
Summary and Conclusions
Joel Greenblatt’s “The Little Book That Beats The Market” has been and continues to be a bestseller in the financial sector – and for good reason. The logic underpinning the methodology for picking stocks makes sense and has produced a good track record of beating the market over time. Although that is not necessarily an investment strategy that is suitable for every investor, there are many who are motivated to build stock portfolios capable of doing just that. Perhaps these 5 small and midcap selections can provide opportunities for those of you that are interested in this course of action. Regardless, I have a lot of fun and found it fascinating and educational to re-read Joel Greenblatt’s book. I especially found it interesting to be able to identify companies that were attractively valued in today’s bifurcated market. Although the market in general appears very high to me, there is also many stocks that appear attractively valued. This offering is for the total return investor. However, I also ran this exercise on larger blue-chip companies with great histories. As one of the co-founders of The Dividend Kings’ marketplace service here on seeking Alpha, I will be providing subscribers an opportunity to review dividend growth stock selections based on Joel Greenblatt’s magic formula.
Disclosure: No Positions.
Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.
Article by F.A.S.T. Graphs